This company has been acquired
Satsuma Pharmaceuticals Dirección
Dirección controles de criterios 2/4
Satsuma Pharmaceuticals' CEO is John Kollins, appointed in Jul 2016, he has a tenure of 6.92 years. His total yearly compensation is $1.91M , comprised of 27.8% salary and 72.2% bonuses, including company stock and options. He directly owns 0.94% of the company’s shares, worth $341.95K. The average tenure of the management team and the board of directors is 5.9 years and 5.8 years respectively.
Información clave
John Kollins
Chief Executive Officer (CEO)
US$1.9m
Compensación total
| Porcentaje del salario del CEO | 27.8% |
| Permanencia del CEO | 6.9yrs |
| Participación del CEO | 0.9% |
| Permanencia media de la dirección | 5.9yrs |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Satsuma shares surge on data from early-stage STS101 trial
Jun 16Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$2m | US$530k | -US$70m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$56m |
| Dec 31 2021 | US$830k | US$500k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$456k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$42m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$391k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$20m |
| Jun 30 2019 | n/a | n/a | -US$13m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$568k | US$362k | -US$7m |
Compensación vs. Mercado: John's total compensation ($USD1.91M) is above average for companies of similar size in the US market ($USD740.57K).
Compensación vs. Ingresos: John's compensation has increased whilst the company is unprofitable.
CEO
John Kollins (60 yo)
6.9yrs
Permanencia
US$1,909,812
Compensación
Mr. John A. Kollins, MBA, has been Director, President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc since July 2016. He served as Chief Business Officer and Senior Vice President of Transcep...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% $ 342.0k | |
| Chief Financial Officer | 4.4yrs | US$936.85k | 0.042% $ 15.3k | |
| VP & Head of Operations | 6.4yrs | sin datos | sin datos | |
| Senior VP & Head of Chemistry | 5.9yrs | sin datos | sin datos | |
| VP & Head of Regulatory Affairs | 5.1yrs | sin datos | sin datos |
5.9yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: STSA's management team is seasoned and experienced (5.9 years average tenure).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.9yrs | US$1.91m | 0.94% $ 342.0k | |
| Independent Director | 2.9yrs | US$132.08k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$131.58k | 0% $ 0 | |
| Independent Chairman of the Board | 6.5yrs | US$160.08k | 0% $ 0 | |
| Independent Director | 6.5yrs | US$120.58k | 0% $ 0 | |
| Independent Director | 1.7yrs | US$124.58k | 0% $ 0 | |
| Independent Director | 7yrs | US$124.08k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$132.08k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$126.08k | 0% $ 0 |
5.8yrs
Permanencia media
59yo
Promedio de edad
Junta con experiencia: STSA's board of directors are considered experienced (5.8 years average tenure).